Preclinical imaging market seen reaching $7.78 billion by 2035

Market Research Future projects the global preclinical imaging market will rise from $4.73 billion in 2025 to $7.78 billion by 2035, driven by biopharmaceutical R&D spending, government research funding and AI-enabled multimodal scanners. North America leads today, while Asia-Pacific is growing fastest as drug development and CRO capacity expand.

Why it matters: - Preclinical imaging is becoming a core tool for earlier drug discovery, candidate validation and translational research. - The market’s projected growth signals stronger demand for non-invasive imaging that can track biological processes over time and reduce reliance on larger animal studies. - The shift matters for oncology, neurology, cardiology and infectious disease research, where quantitative imaging can speed decisions and improve pipeline efficiency.

What happened: - Market Research Future valued the global preclinical imaging market at $4.50 billion in 2024. - The firm projects the market will grow to $4.73 billion in 2025 and reach $7.78 billion by 2035. - The forecast implies a 5.10% CAGR from 2026 through 2035. - The release frames growth around rising pharmaceutical and biotechnology R&D, government biomedical research funding and AI-integrated scanner technology.

The details: - Preclinical imaging platforms provide high-resolution, non-invasive longitudinal views of biological activity in live animal models. - That capability supports efficacy, biodistribution and safety testing earlier in development. - The market is seeing heavier use of hybrid systems, including micro-PET/CT, micro-SPECT/CT and optical imaging. - Optical imaging systems held about 37.2% of market revenue in 2025. - Hybrid and multimodal imaging platforms are the fastest-growing technology category, with growth above 10.1% CAGR. - Oncology was the largest application in 2025, at 42.3% of market share. - Neurology is projected to grow at 10.7% CAGR through 2035. - Pharmaceutical and biotechnology companies accounted for 48.1% of revenue in 2025. - Contract research organizations are the fastest-growing end user, with a projected 12.1% CAGR. - North America held more than 51.0% of the market in 2025. - The United States accounted for over 82% of North American revenue. - Europe held about 24.0% of the market, with Germany leading the region at roughly 28% of regional share. - Asia-Pacific is the fastest-growing region, with a 9.80% CAGR through 2035. - South America is projected to reach $564.9 million by 2035.

Between the lines: - The market outlook reflects a broader push to catch drug-development failures earlier, when they are cheaper to fix. - AI integration is moving preclinical imaging from a hardware-led category toward a software-driven workflow business. - Radiopharmaceuticals and theranostics are increasing demand for nuclear imaging because those programs need organ-level dosimetry and target-specific tracking. - The rise of CRO outsourcing is also reshaping demand, since more sponsors are using external imaging capacity instead of building every platform in-house. - The regional split suggests mature research infrastructure still dominates spending, but manufacturing, trial outsourcing and biomedical investment are shifting faster in Asia-Pacific.

What's next: - The market is expected to become more automated, cloud-integrated and software-driven by 2035. - AI-assisted organ segmentation and lesion tracking are likely to standardize quantitative measurements across multi-center studies. - Benchtop multimodal systems with smaller footprints should make advanced imaging more accessible to mid-tier academic labs and specialty CROs. - The report expects preclinical imaging data to merge more closely with multi-omics datasets in target discovery and AI-assisted drug design.

The bottom line: - Preclinical imaging is moving from a niche research tool to a central platform in drug development, with hybrid systems, AI software and CRO demand driving the next decade of growth.